在非小细胞肺癌细胞中通过CDK12转调替代PD-L1mRNA处理
Trine V Larsen1, Christoffer T Maansson1,2,3, Tina F Daugaard1
1Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark.
这项研究揭示了CDK12调节非小细胞肺癌 (NSCLC) 的PD-L1mRNA处理. CDK12功能的丧失将PD-L1表达转移到可溶性形式,影响免疫治疗反应.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 针对PD-1/PD-L1相互作用的免疫疗法在非小细胞肺癌 (NSCLC) 中显示出前景.
- 患者对PD-1/PD-L1阻塞的反应有所不同,可能是由于PD-L1表达异质.
- PD-L1 mRNA的替代拼接产生可溶性 (sPD-L1) 和膜结合 (mPD-L1) 形式,影响治疗疗效.
研究的目的:
- 确定调节NSCLC细胞中PD-L1mRNA变异比例的因素.
- 研究CDK12在PD-L1替代多基解中的作用.
- 探索CDK12调制对sPD-L1/mPD-L1平衡的影响.
主要方法:
- 在NSCLC细胞系中验证替代PD-L1RNA处理.
- 在分析以确定潜在的监管因素.
- 在CDK12中发生的CRISPR/Cas9中介功能丧失突变.
- 使用CDK12/13抑制剂THZ531.1. 的治疗.
- 对PD-L1mRNA变体和蛋白质异型的定量分析.
主要成果:
- 在NSCLC细胞中证实了产生PD-L1v4 (sPD-L1) 和PD-L1v1 (mPD-L1) 的替代PD-L1RNA处理.
- 在CDK12中失去功能的突变显著增加了PD-L1v4/PD-L1v1mRNA比率.
- 使用THZ531抑制CDK12也提高了PD-L1v4/PD-L1v1比率,并调节了PD-L1对IFN-γ的反应.
- CDK12促进了转录延长,抑制了内部的替代多基解.
结论:
- 在NSCLC中,CDK12在调节可溶性和膜结合的PD-L1异型之间平衡方面发挥着关键作用.
- 调节CDK12活动会影响PD-L1转录变体的形成.
- 研究结果表明CDK12是优化NSCLC中PD-1/PD-L1阻断免疫疗法的潜在目标.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
相关概念视频
Inhibition of Cdk Activity
Abnormal Proliferation
Negative Regulator Molecules
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Regulation of Expression at Multiple Steps
